Intravitreal pefloxacin therapy in postoperative endophthalmitis

Clinical and Experimental Ophthalmology

Volumn 28, Issue 1, 2000, Pages 38-40

  Kumar, A ^a   Sridhar, M S ^a   Dada, T ^a   Tewari, H K ^a   Gupta, S K ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Endophthalmitis; Intravitreal; Pefloxacin; Vitrectomy

Indexed keywords

PEFLOXACIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; ENDOPHTHALMITIS; FEMALE; HUMAN; MALE; RETINA DETACHMENT; STAPHYLOCOCCUS; VISUAL ACUITY; VITRECTOMY;

AGED; ANTI-INFECTIVE AGENTS; CATARACT EXTRACTION; ENDOPHTHALMITIS; EYE INFECTIONS, BACTERIAL; FEMALE; HUMANS; INJECTIONS; LENS IMPLANTATION, INTRAOCULAR; LENSES, INTRAOCULAR; MALE; MIDDLE AGED; PEFLOXACIN; POSTOPERATIVE COMPLICATIONS; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS BODY;

EID: 0033945401     PISSN: 14426404     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1442-9071.2000.00256.x     Document Type: Article

References (16)

1. Speaker MG, Menikoff JA. Postoperative endophthalmitis: pathogenesis, prophylaxis and management. Int. Ophthalmol. Clin. 1993; 33: 51-68.
2. Diamond JG, Intraocular management of endophthalmitis: a systemic approach. Arch. Ophthalmol. 1981; 99: 96-9.
3. Kumar H, Ahuja S, Kumar A. Macular infarction after intravitreal amikacin. Ann. Ophthalmol. 1993; 25: 262-3.
4. Wolfson JS, Hooper DC. The fluoroquinolones: structure, mechanisms of action, resistance and spectra of activity in vitro. Antimicrob. Agents Chemother. 1985; 28: 581-6.
5. Neu HC. Microbiologic aspects of fluoroquinolones. Am. J. Ophthalmol. 1991; 112: 15-24.
6. Iakovlev VP, Alekseev AA, Krutikov MG, Grishina IA, Izotova GN. Use of pefloxacin in the treatment of infected burn wounds. Antibiot. Khimioter. 1996; 41: 39-43.
7. Iakovlev VP, Blatun LA, Khlebnikov EP, Elagina LV, Puchkova LS. Effectiveness of pefloxacin in the surgical clinic. Antibiot. Khimioter. 1995; 40: 43-5.
8. Vollaard EJ, Clasener HA, Janssen AJ. Decontamination of the bowel by intravenous administration of pefloxacin. J. Antimicrob. Chemother. 1990; 26: 847-52.
9. Oncel M. Peyman GA. Intravitreal penetration of oral pefloxacin in humans. Int. Ophthalmol. 1993; 17: 217-22.
10. Bron A, Talon D, Delbosc B, Estavoyer JM, Prost F, Montard M. Intracameral penetration of pefloxacine in man. J. Fr. Ophthalmol. 1986; 9: 317-21.
11. Marrakchi-Benjaafar S, Cochereau I, Pocidalo JJ, Carbon C. Systemic prophylaxis of experimental staphylococcal endophthalmitis; comparative efficacy of sparfloxacin, pefloxacin, vancomycin, and amikacin. J. Infect. Dis. 1995; 172: 1312-16.
12. Nussenblatt RB, Palestine AG, Chan CC. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 1985; 92: 467.
13. Jones RN. Antimicrobial activity and interaction of pefloxacin and its principal metabolites. Collaborative Antimicrobial Susceptibility Testing Group. Eur. J. Clin. Microbial Infect. Dis. 1989; 8: 551-6.
14. Endophthalmitis Vitrectomy Study Group. Results of the Endophthalmitis Vitrectomy Study. Arch. Ophthalmol. 1995; 113: 1470-96.
15. Husson MO, Izard D, Boillet L, Leclere H. In vitro activity of pefloxacin drugs. Exp. Clin. Res. 1986; 12: 313-17.
16. Cochereau-Massin I, Marrakchi-Benjaafar S, Bauchet J, Vallois JM, Faurisson F, D'Hermies F, Pocidalo JJ. Kinetics and tolerability of intravitreal pefloxacin in rabbits. J. Antimicrob. Chemother. 1994; 33: 231-42.